Daily 60mg CBD for 4 weeks did not improve glucose tolerance, modify the gut microbiome, or reduce inflammation in sedentary overweight or obese adults compared to placebo.
Researchers studying cannabis and metabolic health, clinicians advising patients about CBD for metabolic conditions, and supplement consumers.
60mg/day CBD for 4 weeks: no effect on glucose tolerance, gut, or inflammation
What the researchers found
CBD (30mg every 12 hours for 4 weeks) showed no significant effect on glucose tolerance (Matsuda Index), gut microbiome composition, or inflammatory markers compared to placebo in 16 adults with overweight or obesity.
Why it matters
Epidemiological data link cannabis use to lower diabetes rates, and animal studies suggested CBD might improve glucose tolerance through gut microbiome changes. This pilot finds no such effect at low doses in humans.
The numbers in context
16 participants. CBD dose: 30mg every 12 hours (60mg/day). Duration: 4 weeks. Matsuda Index (insulin sensitivity): no significant change (p>0.05). Gut microbiome: no appreciable changes. Inflammation: no modification.
How the study worked
Randomized, double-blind, parallel design pilot study with 16 adults (6 males, 10 females) taking either placebo or CBD 30mg twice daily for 4 weeks, with oral glucose tolerance tests and fecal microbiome analysis at baseline and post-intervention.
What this study cannot tell us
Very small sample (16 participants). Low CBD dose (60mg/day) may be insufficient. Short duration (4 weeks) may not allow metabolic changes to manifest. Sedentary overweight adults may not be the optimal population.
How to read the evidence
Well-designed double-blind RCT but severely underpowered with only 16 participants. Low dose and short duration further limit conclusions.
When this study was published
Published in 2025.
The bigger picture
The cannabis-diabetes paradox seen in population studies may not be explained by CBD specifically, or may require higher doses or longer exposure. Other cannabinoids or the full plant may be responsible for the epidemiological association.
Questions still open
- Would higher CBD doses or longer treatment show effects? Is the cannabis-diabetes link driven by THC or other cannabinoids rather than CBD? Would physically active users show different results?
Common questions
Does CBD help with blood sugar control?
Does CBD change gut bacteria?
Read the original research
Short-Term Low Dose Cannabidiol Does Not Influence Glucose Tolerance or the Gut Microbiome in Sedentary Adults with Overweight and Obesity: Pilot Study.
Cannabis and cannabinoid research
Citation
Ewell, Taylor R; Bomar, Matthew C; Abbotts, Kieran S S; Kayne, Brendan T; Risk, Briana D; Williams, Natasha N B; Wei, Yuren; Dooley, Gregory P; Weir, Tiffany L; Bell, Christopher. (2025). Short-Term Low Dose Cannabidiol Does Not Influence Glucose Tolerance or the Gut Microbiome in Sedentary Adults with Overweight and Obesity: Pilot Study.. Cannabis and cannabinoid research. https://doi.org/10.1177/25785125251391085
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk